Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

BOLD-100 in Combination With FOLFOX for the Treatment of Advanced, Solid Tumours

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04421820
Recruitment Status : Not yet recruiting
First Posted : June 9, 2020
Last Update Posted : June 11, 2020
Sponsor:
Information provided by (Responsible Party):
Bold Therapeutics, Inc.

Brief Summary:
BOLD-100 is an intravenously administered sterile solution containing the ruthenium-based small molecule. BOLD-100 has been shown to preferentially decrease the expression of GRP78 in tumour cells and ER stressed cells when compared to normal cells. BOLD-100 will be combined with cytotoxic FOLFOX chemotherapy in this study, with a dose escalation cohort to ensure tolerability and safety, followed by a cohort expansion phase.

Condition or disease Intervention/treatment Phase
Colorectal Cancer Pancreatic Cancer Gastric Cancers Cholangiocarcinoma Drug: BOLD-100 in combination with FOLFOX Chemotherapy Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 80 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1b Dose Escalation Study of BOLD-100 in Combination With FOLFOX Chemotherapy in Patients With Advanced Solid Tumours
Estimated Study Start Date : August 15, 2020
Estimated Primary Completion Date : December 31, 2021
Estimated Study Completion Date : March 31, 2022


Arm Intervention/treatment
Experimental: Gastric Cancer Drug: BOLD-100 in combination with FOLFOX Chemotherapy
320 mg/m2 IV over 30 minutes, q2weeks; 420 mg/m2 IV over 30 minutes, q2weeks; 500 mg/m2 IV over 30 minutes, q2weeks; 625 mg/m2 IV over 30 minutes, q2weeks

Experimental: Pancreatic Cancer Drug: BOLD-100 in combination with FOLFOX Chemotherapy
320 mg/m2 IV over 30 minutes, q2weeks; 420 mg/m2 IV over 30 minutes, q2weeks; 500 mg/m2 IV over 30 minutes, q2weeks; 625 mg/m2 IV over 30 minutes, q2weeks

Experimental: Colorectal Cancer Drug: BOLD-100 in combination with FOLFOX Chemotherapy
320 mg/m2 IV over 30 minutes, q2weeks; 420 mg/m2 IV over 30 minutes, q2weeks; 500 mg/m2 IV over 30 minutes, q2weeks; 625 mg/m2 IV over 30 minutes, q2weeks

Experimental: Cholangiocarcinoma Drug: BOLD-100 in combination with FOLFOX Chemotherapy
320 mg/m2 IV over 30 minutes, q2weeks; 420 mg/m2 IV over 30 minutes, q2weeks; 500 mg/m2 IV over 30 minutes, q2weeks; 625 mg/m2 IV over 30 minutes, q2weeks




Primary Outcome Measures :
  1. Incidence and severity of adverse events (AEs) according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 5.0 [ Time Frame: Screening to Study Discontinuation (an average of 2 months) ]
  2. Incidence of serious adverse events (SAE) and suspected unexpected serious adverse reactions; [ Time Frame: Screening to Study Discontinuation (an average of 2 months) ]
  3. Incidence of dose-limiting toxicities (DLT) [ Time Frame: Screening to Study Discontinuation (an average of 2 months) ]
  4. Incidence of clinically significant changes or abnormalities from Physical Examinations, ECGs, Vital Signs, Laboratory Results (chemistry, hematology, coagulation, urinalysis), Eastern Cooperative Oncology Group (ECOG) performance status [ Time Frame: Screening to Study Discontinuation (an average of 2 months) ]

Secondary Outcome Measures :
  1. Progression Free Survival (PFS); Overall Response Rate (ORR); Overall Survival (OS) [ Time Frame: Screening to Study Discontinuation (an average of 2 months) ]
  2. Standard PK parameters including Cmin [ Time Frame: Screening to Study Discontinuation (an average of 2 months) ]
  3. Baseline GRP78 biomarker levels (Counts/mL) [ Time Frame: Baseline ]
  4. Changes in GRP78 biomarker levels during treatment (Counts/mL) [ Time Frame: Screening to Study Discontinuation (an average of 2 months) ]
  5. Standard PK parameters including Cmax [ Time Frame: Screening to Study Discontinuation (an average of 2 months) ]
  6. Standard PK parameters including TSS [ Time Frame: Screening to Study Discontinuation (an average of 2 months) ]
  7. Standard PK parameters including CSS [ Time Frame: Screening to Study Discontinuation (an average of 2 months) ]
  8. Standard PK parameters including Vdss [ Time Frame: Screening to Study Discontinuation (an average of 2 months) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Be 18 years or older.
  2. Be male or non-pregnant females who agree to comply with applicable contraceptive requirements of the protocol (see Table 12. Acceptable Contraceptive Methods.)
  3. Histologically and/or cytologically confirmed gastrointestinal tumours that are metastatic or unresectable, and have received at least one line of chemotherapy in the metastatic setting (in the dose escalation phase only). For the dose expansion phase, the setting will vary based on the malignancy. Colorectal cancer: Patients must have received at least 1 prior line of therapy prior to enrollment in this study. Pancreatic cancer: Patients must have received at least 1 prior line of therapy. Gastric cancer: Patients who have not received prior treatment may be included in this study. Cholangiocarcinoma: Patients must have received at least 1 prior line of therapy (with gemcitabine-based chemotherapy).
  4. Have measurable disease according to RECIST v1.1 (at least one measurable lesion).
  5. Have an anticipated survival of at least 16 weeks.
  6. Be ambulatory, with an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1.
  7. Have adequate organ function, defined as:

    1. Hematologic: ANC ≥ 1.5 x 109/L, Hgb ≥ 9.0 g/dL and platelet count ≥ 100 x 109/L
    2. Hepatic: total bilirubin ≤ 1.5 x ULN; transaminases ≤ 2.5 x ULN (may be up to 5 x ULN if clearly due to liver metastases), ALP ≤ 2.5 x ULN
    3. Renal: serum creatinine ≤ 1.5 x ULN or creatinine clearance ≥ 50 mL/min.

    c. Urine protein is 0, trace, or +1 on dipstick urinalysis, or < 1.0 gram on 24-hour urine protein analysis

  8. Be on stable doses of any drugs that may affect hepatic drug metabolism or renal drug excretion (e.g., non-steroidal anti-inflammatory drugs, corticosteroids, barbiturates, diphenylhydantoin, narcotic analgesics, probenecid). Such drugs should not be initiated while the subject is participating in this study or have been initiated within 30 days beforehand. Whenever possible, narcotic analgesic doses should be stable within 30 days prior to study entry and during the first cycle of therapy.
  9. Resolved acute effects of any prior therapy to baseline severity or grade ≤1 CTCAE 5.0 except for adverse events not constituting a safety risk by investigator judgment (such as alopecia)
  10. Able to take oral medications (for pre-medications and supportive management)
  11. Understand and be able, willing, and likely to fully comply with study procedures and restrictions.
  12. Be fully informed about their illness and the investigational nature of the study protocol, and sign a REB-approved Informed Consent Form (ICF).

Exclusion Criteria:

  1. Neuropathy > grade 2
  2. Previous intolerance to or significant reaction secondary to fluorouracil or oxaliplatin
  3. Cerebrovascular accident within the past 6 months.
  4. History or presence of central nervous system (CNS) metastasis or leptomeningeal tumours as documented by CT or MRI scan, analysis of cerebrospinal fluid or neurological exam.
  5. Any serious medical conditions that might be aggravated by treatment or limit compliance. This includes, but is not limited to uncontrolled psychiatric disorders, serious infections, active peptic ulcer disease and bleeding diathesis
  6. Any history of serious cardiac illness including (but not confined to):

    • Previous or active myocardial infarction < 6 months
    • Congestive cardiac failure (NYHA III or IV)
    • History of unstable angina pectoris < 6 months
    • Recent coronary artery bypass grafting < 6 months
    • Uncontrolled hypertension (systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg)
    • Ventricular arrhythmia < 6 months
    • Left ventricular ejection fraction (LVEF) < 50% as measured either by radionuclide angiography or echocardiogram
    • QTc interval > 470 msec
  7. Hemoptysis, cerebral, or clinically significant gastrointestinal hemorrhage in the past 6 months
  8. Any other known malignancy within 3 years (with the exception of non-melanoma skin cancer that had undergone curative treatment, cervical cancer in situ, or ductal/lobular carcinoma in situ of the breast that has underwent local treatment
  9. Active gastrointestinal tract disease with malabsorption syndrome.
  10. Non-healing wound, fracture, or ulcer, or presence of symptomatic peripheral vascular disease.
  11. Treatment with radiation therapy or surgery within one month prior to study entry.
  12. Recent history of weight loss > 10% of current body weight in past 3 months.
  13. Current (within 1 week of the start of the study) or regular use of any medication (including OTC, herbal or homeopathic preparations) that could affect (improve or worsen) the cancer being studied, or could affect the action or disposition of BOLD-100, or its clinical or laboratory assessment, e.g., Coumadin therapy, due to high competitive protein binding. Subjects taking ANY supplemental IRON, i.e., therapeutic or as part of a multivitamin regimen, are excluded from this study, whether prescribed or self-medicated.
  14. HIV-positive subjects on combination anti-retroviral therapy due to the potential for PK interactions with the study agent.
  15. Any condition potentially decreasing compliance to study procedures. Concurrent use of another investigational therapy or anti-cancer therapy.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04421820


Contacts
Layout table for location contacts
Contact: Michelle Jones 604-262-9899 clinical@bold-therapeutics.com
Contact: Jim Pankovich 604-262-9934 jp@bold-therapeutics.com

Locations
Layout table for location information
Canada, Alberta
Health Research Ethics Board of Alberta Cancer Committee
Edmonton, Alberta, Canada, T5J 4A7
Contact: Jacqueline Senych    780-999-679      
Canada, Quebec
MUHC Centre for Applied Ethics
Montréal, Quebec, Canada, H4A 3T2
Contact    514-934-1934 ext 34323    cae@muhc.mcgill.ca   
Sponsors and Collaborators
Bold Therapeutics, Inc.
Layout table for additonal information
Responsible Party: Bold Therapeutics, Inc.
ClinicalTrials.gov Identifier: NCT04421820    
Other Study ID Numbers: BOLD-100-001
First Posted: June 9, 2020    Key Record Dates
Last Update Posted: June 11, 2020
Last Verified: June 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Cholangiocarcinoma
Neoplasms
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type